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COVID-19 may predispose to both venous and arterial thromboembolism event (TEE).
Reports on the prevalence and prognosis of thrombotic complications are still emerging.
Objective
To describe the rate of TEE complications and its influence in the prognosis of hospitalized
patients with COVID-19 after a cross-sectional study.
Methods
We evaluated the prevalence of TEE and its relationship with in-hospital death among hos-
pitalized patients with COVID-19 who were admitted between 1st March to 20th April 2020
in a multicentric network of sixteen Hospitals in Spain. TEE was defined by the occurrence
of venous thromboembolism (VTE), acute ischemic stroke (AIS), systemic arterial embolism
or myocardial infarction (MI).
Results
We studied 1737 patients with proven COVID-19 infection of whom 276 died (15.9%). TEE
were presented in 64 (3.7%) patients: 49 (76.6%) patients had a VTE, 8 (12.5%) patients
had MI, 6 (9.4%%) patients had AIS, and one (1.5%) patient a thrombosis of portal vein.
TEE patients exhibited a diffuse profile: older, high levels of D-dimer protein and a tendency
of lower levels of prothrombin. The multivariate regression models, confirmed the associa-
tion between in-hospital death and age (odds ratio [OR] 1.12 [95% CI 1.10–1.14], p<0.001),
diabetes (OR 1.49 [95% CI 1.04–2.13], p = 0.029), chronic obstructive pulmonary disease
(OR 1.61 [95% CI 1.03–2.53], p = 0.039), ICU care (OR 9.39 [95% CI 5.69–15.51],
p<0.001), and TTE (OR 2.24 [95% CI 1.17–4.29], p = 0.015).
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Conclusions
Special attention is needed among hospitalized COVID-19 patients with TTE and other
comorbidities as they have an increased risk of in-hospital death.
Introduction
The coronavirus disease of 2019 (COVID-19) is a viral illness caused by the severe acute respi-
ratory syndrome coronavirus 2 (SARS-CoV2) that is now considered a pandemic by the
World Health Organization [1–3]. Although, initial efforts have been focused on the diagnosis
and treatment of severe pneumonia with vital compromise [1, 3], a spectrum of extra respira-
tory symptoms and signs generated by the infection itself have been verified. Among those
symptoms, we can stand out that COVID-19 infection might predispose patients to throm-
botic disease, both in the venous and arterial circulations mediated by inflammation, endothe-
lial dysfunction, thrombin generation, platelet activation and stasis [4, 5]. Recently, it was
reported a 31% prevalence of thrombotic complications in ICU patients with COVID-19 infec-
tions in Dutch intensive care units [6]. Coagulopathy and over disseminated intravascular
coagulation appear to be associated with high mortality rates. Among the coagulation parame-
ters, D-dimer elevation was the strongest independent predictor of mortality [7], and high lev-
els of D-dimer have been observed in patients admitted to intensive care units [1]. Non-
survivors have shown significantly higher levels of plasma D-dimers and fibrin degradation
products, increased prothrombin times and activated partial thromboplastin times compared
to survivors [8]. Moreover, the metallopeptidase enzyme of angiotensinogen converter 2
(ACE2), identified as the cellular receptor for the coronavirus, is expressed in alveolar epithe-
lial cells and in endothelial cells [9]. The prothrombotic predisposition seems to be developed
more intensely from the tenth day of infection [10], and it would also be related to the inflam-
matory effect of the COVID-19 infection.
The relationship between inflammation and ischemic episodes is already described [11, 12]
and COVID-19 associated ischemic strokes are more severe with worse functional outcome
and higher mortality than non-COVID-19 ischemic strokes patients [13, 14]. COVID-19 has a
number of important cardiovascular implications [15–17]. There is a high prevalence of car-
diovascular disease among patients with COVID-19 and acute cardiac injury is commonly
observed in severe cases. Patients with prior risk factors are at higher risk for adverse events
from COVID- 19 and worse prognosis [18, 19].
Here, we evaluated the prevalence of thromboembolism event (TEE) in all COVID-19
patients admitted to the network of 16 Hospitals in Spain (HM Hospitals). The influence of
the composite outcome in the risk of death during the admission was also determined.
Material and methods
Data source
This is a cohort study based on anonymized clinical dataset provided by HM Hospitales,
which includes sixteen hospitals from all over Spain (HM Delfos, HM Sant Jordi, HM nens,
HM modelo, HM Belén, HM Rosaleda, HM la esperanza, HM San Francisco, HM regla, HM
Madird, HM Monteprı́ncipe, HM Torrelodones, HM Sanchinarro, HM Nuevo Belén, HM
Puerta del Sur and HM Vallés), with detailed hospital admission information for COVID-19
patients from March 1st to April 20th 2020. Database was accessed by the research on August
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2020. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
guidelines were applied [20].
Study participants
A dedicated electronic medical record data extraction protocol was developed to identify all patients
with confirmed COVID-19 (defined as a positive SARS-CoV2 reverse-transcriptase polymerase
chain reaction test by nasopharyngeal/oropharyngeal swab or sputum specimen). Patients whose
age was under 18 years were excluded (n = 11) (Fig 1). We retrieved the primary International Clas-
sification of Diseases (ICD10, 10th Revision, Clinical Modification) codes for each patient. For the
selected patients, clinical characteristics, demographic variables, admission at ICU, laboratory deter-
minations, coexisting conditions and vascular risk factors based on ICD10 were collected for fur-
ther analysis. Patients without ICD10 codification were also excluded (n = 131) (Fig 1).
The primary outcome was the occurrence of TEE defined by venous thromboembolism
(VTE), acute ischemic stroke (AIS), systemic arterial embolism or myocardial infarction. The
relationship of TEE with the endpoint of in-hospital discharged or exitus was also evaluated.
Fig 1. Patients flowchart.
https://doi.org/10.1371/journal.pone.0252351.g001
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Data analysis
Categorical variables were presented as numbers and percentages and continuous variables as
mean and standard deviation if they were normally distributed or median and interquartile
range if they were not normally distributed. Variables related to the composite outcome and
death were identified. We compared means for continuous variables by using independent
group t-tests when the data was normally distributed; otherwise, we used the Mann-Whitney
test. Proportions for categorical variables were compared using the chi-square (χ2) test. Fish-
er’s exact test was used in the analysis of contingency when the sample sizes were small. Multi-
variate logistic regression analysis was used to identify predictors of death, in which variables
showing p�0.10 on a univariate testing were included. Forward selection model with likeli-
hood ratio (LR) was used, first demographic and clinical characteristics (model 1) were added
and vital signs (model 2) were added afterwards, to analyze the single best improvement of the
model. All the tests were 2-sided and were run at a statistical significance level of p�0.05. Data
was analyzed using SPSS Statistics software, version 20 (IBM SPSS, Chicago, IL, USA).
The study was approved by the Ethics committee of the HM Hospitals (approval number
20.03.1573-GHM).and adhered to the policy for protection of human subjects according to
Declaration of Helsinki. As the information was obtained from a de-identified public database
written informed consent for our specific study from all study participants was not needed.
The data were analyzed anonymously.
Results
A total of 1737 patients (Fig 1) were included in the current analysis, all of them were
COVID-19 positive. Of those, 64 (3.7%) patients had a TEE: 49 (76.6%) patients had a VTE,
8 (12.5%) patients had an acute ischemic heart disease event, 6 (9.4%%) patients had an AIS,
and one (1.5%) patient a thrombosis of portal vein. Median time from admission to discharge
was 7 (interquartile range [IQR], 4.0–10.0) days. The main diagnosis at admission was pneu-
monia or respiratory symptoms present in 1606 (92.5%) patients. Hypertension was the main
vascular risk factor presented in 647 (37.2%) patients. 117 (6.7%) patients required intensive
care. 276 patients died after hospital’s admission, corresponding to an in-hospital mortality
rate of 15.9%. Median time until death was 5.0 days (IQR 3.0–9.0) days.
Variables associated with thromboembolic events
Dataset was clustered by the absence/presence of TEE (Table 1). The group of TEE was charac-
terized by older patients (mean age 68.9 [standard deviation, SD:14.0] vs. 65.3 [SD:16.7] years,
p = 0.097). TEE patients had signicantly less pneumonia or respiratory symptoms at admission
than non-TEE patients. (75.0% versus 93.1%, p<0.001). Mortality risk during admission was
significant higher in TEE patients than in non-TEE patients (29.7% [95% CI 18.5–40.9] vs.
15.4% [95% CI 13.7–17.1], p = 0.002). No descriptive variables nor previous coexisting condi-
tions or vascular risk factors were significantly associated with TEE. D-dimer levels were sig-
nificantly higher among TEE patients than in non-TEE patients (median 6679.0 [IQR 661.0–
11297.0] vs. 742.5 [IQR 425.0–1496.0] ng/mL, p = 0.009); and prothrombin time showed a
lower tendency in TEE patients (median 12.6 [IQR 11.9–13.2] vs. 13.3 [IQR 12.4–14.6] sec-
onds, p = 0.056) (Table 1).
Associations of in-hospital mortality
Non-survivor patients were significantly older than survivor patients (mean 80.7 [SD 9.7] vs.
62.6 [SD 9.7] years, p<0.001). A higher prevalence of risk factors was also presence in the
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group of non-survivors: hypertension (51.8% vs. 34.5%, p<0.001), diabetes mellitus (25% vs.
13.3%, p<0.001), hyperlipidemia (27.2% vs. 21.6%, p = 0.040), chronic kidney disease (8.7%
vs. 2.7%, p<0.001), congestive heart failure (4.7% vs. 1.7%, p = 0.002), chronic obstructive pul-
monary disease (15.6% vs. 5.2%, p<0.001), and atrial fibrillation (8.3%) (Table 2). Mortality
was higher in patients initially admitted to intensive care unit than in conventional units
(16.3% vs. 4.9%, p<0.001).
Table 1. Description and frequency of baseline characteristics, comorbidity, clinical, laboratory variables in patients with thromboembolic events.
All Non-TEE TEE p-valuea
n (%) 1737 1673 (96.3) 64 (3.7) -
Age, mean (SD), years 65.5 (16.7) 65.3 (16.7) 68.9 (14.0) 0.097
Sex female 686 (39.5) 660 (39.5) 26 (40.6) 0.850
Hypertension 647 (37.2) 622 (37.2) 25 (39.1) 0.760
Diabetes 263 (15.1) 255 (15.2) 8 (12.5) 0.548
Hyperlipidemia 390 (22.5) 376 (22.5) 14 (21.9) 0.910
Chronic kidney disease 64 (3.7) 63 (3.8) 1 (1.6) 0.358
Congestive heart failure 38 (2.2) 35 (2.1) 3 (4.7) 0.164
Atrial fibrillation 72 (4.1) 70 (4.2) 2 (3.1) 0.677
Previous ischemic heart disease 91 (5.2) 89 (5.3) 2 (3.1) 0.439
Previous cerebrovascular disease 15 (0.9) 14 (0.8) 1 (1.6) 0.538
Pneumonia or respiratory symptoms 1606 (92.5) 1558 (93.1) 48 (75.0) <0.001
Chronic obstructive pulmonary disease 119 (6.9) 112 (6.7) 7 (10.9) 0.187
Ex-smoker 258 (14.9) 246 (14.7) 12 (18.8) 0.372
Current smoker 52 (3.0) 50 (3.0) 2 (3.1) 0.950
Management
ICU admission 117 (6.7) 110 (6.6) 7 (10.9) 0.172
Days of hospitalization, median (IQR) 7.0 (4.0–10.0) 7.0 (4.0–10.0) 7.5 (4.0–13.0) 0.118
Death 276 (15.9) 257 (15.4) 19 (29.7) 0.002
Vital signs
Systolic blood pressure, mean (SD) mmHg N = 1099 131.5 (21.5) 131.4 (21.4) 132.2 (22.3) 0.799
Diastolic blood pressure, mean (SD) mmHg N = 1104 76.5 (33.0) 76.4 (33.6) 78.6 (14.2) 0.643
Oxygen saturation, mean (SD) N = 1385 92.3 (7.0) 92.3 (7.0) 91.4 (7.4) 0.357
Laboratory determinations
D-dimer, median (IQR) ng/mL N = 257 822.5 (450.5–1745.5) 742.5 (425.0–1496.0) 6679.0 (661.0–11297.0) 0.009
Alanine aminotransferase, median (IQR) U/L N = 277 28.2 (17.0–49.0) 27.1 (17.0–46.7) 37.0 (23.8–67.1) 0.343
Aspartate aminotransferase, median (IQR) U/L N = 284 34.0 (23.8–57.1) 33.0 (23.3–56.3) 43.5 (25.0–78.2) 0.265
Creatinine, median (IQR) mg/dL N = 304 0.9 (0.7–1.1) 0.9 (0.7–1.1) 0.8 (0.7–0.9) 0.232
Hemoglobin, median (IQR) g/dL N = 297 13.6 (12.2–14.8) 13.7 (12.5–14.8) 14.1 (11.6–15.9) 0.696
Leukocytes, median (IQR) x10e3/μL N = 308 6.6 (5.0–9.5) 6.4 (4.9–8.9) 6.8 (5.0–9.1) 0.857
Neutrophil count, median (IQR) x10e3/μL N = 308 4.8 (3.3–7.6) 4.6 (3.3–7.1) 4.9 (3.3–7.6) 0.772
Platelet count, median (IQR) x103 per uL N = 302 218.5 (168.3–299.5) 214.0 (165.5–301.0) 240.0 (209.5–271.5) 0.493
C reactive protein, median (IQR) mg/dl N = 288 61.8 (24.2–118.6) 60.3 (22.9–122.2) 89.5 (33.0–135.7) 0.279
Prothrombin time, median (IQR) s N = 259 13.2 (12.3–14.5) 13.3 (12.4–14.6) 12.6 (11.9–13.2) 0.056
Values are presented as n (%) or mean ± SD unless otherwise stated. Statistically significant results are highlighted in bold. Abbreviations: Non-TEE: non-
thromboembolic event. TEE: thromboembolic event. Reference ranges are as follows: d-dimer, 0 to 500 ng per milliliter; alanine aminotransferase (ALT), U/L <33–41;
aspartate aminotransferase (AST), U/L <33–41; creatinine, mg/dL (0.7–1.2) mg/dL (0.5–0.9); hemoglobin, g/dL (12.3–15.3) (14.0–17.5); leukocytes, x10e3/μL (4.4–
11.3); neutrophil count, x10e3/μL (1.5–7.5); platelet count, 150,000 to 450,000 per cubic microliter; C reactive protein, mg/L <5; prothrombin time, 9.9 to 14.2 seconds.
Abbreviations: SD, standard deviation; IQR, interquartile range; ICU, intensive care unit.
https://doi.org/10.1371/journal.pone.0252351.t001
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Monitored vital signs were also altered in non-survivor patients. Basal systolic blood pres-
sure (mean 129.8 [SD 25.9] vs. 131.9 [SD 20.4] mmHg, p<0.001) and oxygen saturation (mean
86.2% [SD 11.4] vs. 93.4% [SD 5.3], p = 0.018) were significantly reduced in non-survivor
patients.
Table 2. Demographic and clinical findings among COVID-19 patients with thromboembolic events, stratified by mortality.
All Survivors Non survivors p-valuea
n (%) 1737 1461 (84.1) 276 (15.9) -
Age, mean (SD) years 65.5 (16.7) 62.6 (16.2) 80.7 (9.7) <0.001
Sex female 686 (39.5) 589 (40.3) 97 (35.1) 0.107
Hypertension 647 (37.2) 504 (34.5) 143 (51.8) <0.001
Diabetes 263 (15.1) 194 (13.3) 69 (25.0) <0.001
Hyperlipidemia 390 (22.5) 315 (21.6) 75 (27.2) 0.040
Chronic kidney disease 64 (3.7) 40 (2.7) 24 (8.7) <0.001
Congestive heart failure 38 (2.2) 25 (1.7) 13 (4.7) 0.002
Atrial fibrillation 72 (4.1) 49 (3.4) 23 (8.3) <0.001
Previous ischemic heart disease 91 (5.2) 61 (4.2) 30 (10.9) <0.001
Previous cerebrovascular disease 15 (0.9) 10 (0.7) 5 (1.8) 0.063
Pneumonia or respiratory symptoms 1606 (92.5) 1353 (92.6) 253 (91.7) 0.587
Chronic obstructive pulmonary disease 119 (6.9) 76 (5.2) 43 (15.6) <0.001
Ex-smoker 258 (14.9) 213 (14.6) 45 (16.3) 0.460
Current smoker 52 (3.0) 45 (3.1) 7 (2.5) 0.627
Management
ICU care 117 (6.7) 72 (4.9) 45 (16.3) <0.001
Days of hospitalization, median (IQR) 7.0 (4.0–10.0) 7.0 (4.0–10.0) 5.0 (3.0–9.0) <0.001
Thromboembolism Event 64 (3.7) 45 (3.1) 19 (6.9) 0.002
Venous thromboembolism 49 (2.8) 35 (2.4) 14 (5.1) 0.014
Acute ischemic stroke 6 (0.3) 3 (0.2) 3 (1.1) 0.022
Acute ischemic heart disease 8 (0.5) 5 (0.3) 3 (1.1) 0.094
Vital signs
Systolic blood pressure, mean (SD) mmHg N = 1099 131.5 (21.5) 131.9 (20.4) 129.8 (25.9) <0.001
Diastolic blood pressure, mean (SD) mmHg N = 1104 76.5 (33.0) 77.6 (35.7) 71.3 (14.2) 0.242
Oxygen saturation, mean (SD) N = 1385 92.3 (7.1) 93.4 (5.3) 86.2 (11.4) 0.018
Laboratory determinations
D-dimer, median (IQR) ng/mL N = 257 822.5 (450.5–1745.5) 690.0 (403.0–1217.0) 3321.0 (1003.5–6526.0) <0.001
Alanine aminotransferase, median (IQR) U/L N = 277 28.2 (17.0–49.0) 27.4 (17.7–46.9) 26.1 (15.5–51.1) 0.816
Aspartate aminotransferase, median (IQR) U/L N = 284 34.0 (23.8–57.1) 31.0 (22.8–51.9) 46.2 (25.9–65.1) 0.007
Creatinine, median (IQR) mg/dL N = 304 0.9 (0.7–1.1) 0.8 (0.7–1.0) 1.0 (0.8–1.7) 0.001
Hemoglobin, median (IQR) g/dL N = 297 13.6 (12.2–14.8) 13.9 (12.6–14.9) 12.7 (11.8–13.8) 0.001
Leukocytes count, median (IQR) x10e3/μL N = 308 6.6 (5.0–9.5) 6.1 (4.9–8.5) 8.4 (5.7–10.8) 0.001
Neutrophil count, median (IQR) x10e3/μL N = 308 4.8 (3.3–7.6) 4.4 (3.2–6.4) 7.3 (4.1–11.1) <0.001
Platelets count, median (IQR) x103 per uL N = 302 218.5 (168.3–299.5) 224.5 (171.0–311.0) 185.0 (141.0–240.0) 0.002
C reactive protein, median (IQR) mg/dl N = 288 61.8 (24.2–118.6) 54.5 (21.7–107.7) 129.7 (48.2–238.9) <0.001
Prothrombin time, median (IQR) seconds N = 259 13.2 (12.3–14.5) 13.2 (12.3–14.5) 13.8 (12.8–15.2) 0.039
Values are presented as n (%) or mean ± SD unless otherwise stated. Statistically significant results are highlighted in bold. Reference ranges are as follows: d-dimer, 0 to
500 ng per milliliter; alanine aminotransferase (ALT), U/L <33–41; aspartate aminotransferase (AST), U/L <33–41; creatinine, mg/dL (0.7–1.2) mg/dL (0.5–0.9);
hemoglobin, g/dL (12.3–15.3) (14.0–17.5); leukocytes, x10e3/μL (4.4–11.3); neutrophil count, x10e3/μL (1.5–7.5); platelet count, 150,000 to 450,000 per cubic microliter;
C reactive protein, mg/L <5; prothrombin time, 9.9 to 14.2 seconds.
Abbreviations: SD, standard deviation; IQR, interquartile range; ICU, intensive care unit.
https://doi.org/10.1371/journal.pone.0252351.t002
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The thrombotic profile of non-survivor patients was characterized by elevated levels of d-
dimer (median 3321.0 [IQR 1003.5–6526.0] vs. 690.0 [IQR 403.0–1217.0] ng/mL, p<0.001),
and prolonged prothrombin time suggesting coagulopathy (median 13.8 [IQR 12.8–15.2] vs.
13.2 [IQR 12.3–14.5] seconds, p = 0.039). The influence of inflammation and immune
response was showed by elevated levels of c-reactive protein (median 129.7 [IQR 48.2–238.9]
vs. 54.5 [IQR 21.7–107.7] mg/dl, p<0.001) and higher counts of leukocytes (median 8.4 [IQR
5.7–10.8] vs. 6.1 [IQR 4.9–8.5] x10e3/uL, p = 0.001) and neurotrophils (median 7.3 [IQR 4.1–
11.1] vs. 4.4 [3.2–6.4] x10e3/uL, p<0.001) among non-survivor patients. Finally, hemoglobin
(median 12.7 [IQR 11.8–13.8] vs. 13.9 [IQR 12.6–14.9] g/dL, p = 0.001) and platelets (median
185.0 [IQR 141.0–240.0] vs. 224.5 [IQR 171.0–311.0] x10e3/uL, p = 0.002) counts were
decreased in non-survivor patients (Table 2).
The multivariate regression models confirmed the association between in-hospital death
and age (odds ratio [OR] 1.12 [95% CI 1.10–1.14], p<0.001), diabetes (OR 1.49 [95% CI 1.04–
2.13], p = 0.029), chronic obstructive pulmonary disease (OR 1.61 [95% CI 1.03–2.53],
p = 0.039), ICU care (OR 9.39 [95% CI 5.69–15.51], p<0.001), and thromboembolism pres-
ence (OR 2.24 [95% CI 1.17–4.29], p = 0.015). In addition, basal systolic blood pressure (OR
0.98 [95% CI 0.98–0.99], p<0.001) and basal oxygen saturation (OR 0.90 [95% CI 0.88–0.93],
p<0.001) were inversely related to the risk of in-hospital mortality (Table 3).
Discussion
Our results showed a deleterious effect of TEE, age, diabetes mellitus, and COPD in in-hospital
mortality among COVID-19 patients (Table 3). Previous reports identified both the relation-
ship of COVID-19 infection and TEE [5, 6, 21–23] and the increased risk of death among
TEE patients [24]. However, most of them have been limited in size and focused on patients
with severe disease hospitalized in intensive care units. These aspects could explain the signifi-
cantly lower observed TEE risk in our investigation than in others. We have confirmed the
association of D-dimer levels and TEE events [24]. In initial reports of COVID-19 infection,
D-dimers levels and prolonged prothrombin time have defined a coagulation disorder associ-
ated with COVID-19 infection severity [1]. In line with this hypothesis, recent autopsy studies
identified extensive extracellular fibrin deposition and the presence of fibrin thrombi within
small vessels and capillaries of the lungs [25–27]. As in our study, VTE is the most described
thrombotic complication [6, 28]. COVID-19 infection was also associated with hyperviscocity,
which could explain anticoagulation failures [29]. Moreover, in cases of sepsis the overproduc-
tion of proinflammatory cytokines can cause microvasculature and endothelial dysfunction,
Table 3. Multivariate analysis and adjusted logistic regression for predictors of death.
Variables Model 1 Model 2
OR (CI 95%) p-value OR (CI 95%) p-value
Age 1.12 (1.10–1.14) <0.001 1.12 (1.09–1.14) <0.001
Diabetes 1.49 (1.04–2.13) 0.029 2.04 (1.28–3.25) 0.003
Chronic obstructive pulmonary disease 1.61 (1.03–2.53) 0.039 1.81 (1.00–3.27) 0.049
ICU care 9.40 (5.69–15.51) <0.001 4.86 (2.34–10.08) <0.001
Thromboembolism 2.24 (1.17–4.29) 0.015 2.46 (1.11–5.45) 0.027
Systolic blood pressure - - 0.98 (0.98–0.99) <0.001
Oxygen saturation - - 0.90 (0.88–0.93) <0.001
Multivariate analysis exploring the predictors of death in COVID-19 patients. Statistically significant results are highlighted in bold. Abbreviations: OR: odds ratio; CI:
confidence interval.
https://doi.org/10.1371/journal.pone.0252351.t003
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which could trigger hemostatic cascade [30]. In addition, the prothrombotic effect of COVID-
19 infection might be related with the risk of developing acute coronary syndrome, that
increases on acute infections like influenza epidemics [31–33] due to the increment of myocar-
dial demands triggered by infections [34]. Also, there is an evidence of increasing in-hospital
mortality among patients with myocardial injury associated with elevated troponin T levels
[35, 36]. As well, a direct viral infection of vascular endothelium and myocardium is possible
[37, 38]. Stroke mechanisms include hypercoagulability and cardioembolic stroke of cited
virus-related with cardiac injury [10]. The absence of association between general risk factors
for TEE in our cohort was similar with previous studies [6, 39].
As in other respiratory viral infections [31, 40], we observed that old patients [7, 41, 42] and
COPD [43] were associated with a higher risk of poor outcomes or death. Recent data indicate
that diabetes is an important risk factor for unfavorable outcome in COVID-19 patients. How-
ever, most of the studies described a small number of cases [7, 19, 42]. Our investigation
included enough patients to demonstrated independent predictive value of this risk factor on
mortality. This relationship could be partially explained because diabetic patients are predis-
posed to a hyper-inflammatory and pro-coagulant state [44]. COVID-19 infection could cause
pleiotropic alterations of glucose metabolism due to direct effect on angiotensin-converting
enzyme 2 (ACE2) receptors of pancreatic beta cells [45].
Our study has some important limitations as well. First, the retrospective nature of the
study might constraint the dataset. Second, we analyzed data supplied by HM Hospitales and
it would have been beneficial to perform a revision of the electronic medical records of the
included patients, concretely the TEE group to refine some of the variables and get a deeper
description. Third, information of previous treatments like anticoagulants or antiplatelet
agents was not available. Fourth, we were not able to evaluate a relevant cofounder such as the
motivation of hospitalization (clinical or surgical). These limitations avoid us making a recom-
mendation of thrombosis prophylaxis although, due to the large number of patients included
we considered that our sample is representative of a larger population. A recent meta-analysis
concluded that there is currently insufficient evidence to determine the risks and benefits of
prophylactic anticoagulants for people hospitalized with COVID-19 [46].
In conclusion, the analysis of this multicenter retrospective observational dataset of
COVID-19 patients confirmed some of the previous observations related with TEE in
COVID-19 patients. The prevalence of TEE was not negligible. In addition, patients who
develop TEE such as patients with other comorbidities as diabetes, COPD, and older patients
had worse prognosis than patient without TEE or theses comorbidities.
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Methodology: Francisco Purroy, Gloria Arqué.
Project administration: Francisco Purroy.
Software: Francisco Purroy.
Supervision: Francisco Purroy, Gloria Arqué.
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References
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel
coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. Epub 2020/01/28. https://doi.org/10.
1016/S0140-6736(20)30183-5 PMID: 31986264; PubMed Central PMCID: PMC7159299.
2. World Health World Health Organization. Coronavirus Disease 2019 (COVID-19) Situation report—46.
Available Online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200714-
covid-19-sitrep-176.pdf?sfvrsn=d01ce263_2 (Accessed on July 14th 2020)].
3. Lipsitch M, Swerdlow DL, Finelli L. Defining the Epidemiology of Covid-19—Studies Needed. N Engl J
Med. 2020; 382(13):1194–6. Epub 2020/02/20. https://doi.org/10.1056/NEJMp2002125 PMID:
32074416.
4. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic
or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up:
JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(23):2950–73. Epub 2020/04/21. https://doi.
org/10.1016/j.jacc.2020.04.031 PMID: 32311448; PubMed Central PMCID: PMC7164881.
5. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe
novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(6):1421–4. Epub 2020/04/10. https://doi.
org/10.1111/jth.14830 PMID: 32271988; PubMed Central PMCID: PMC7262324.
6. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic
complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145–7. Epub 2020/04/
16. https://doi.org/10.1016/j.thromres.2020.04.013 PMID: 32291094; PubMed Central PMCID:
PMC7146714.
7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpa-
tients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054–
62. Epub 2020/03/15. https://doi.org/10.1016/S0140-6736(20)30566-3 PMID: 32171076; PubMed Cen-
tral PMCID: PMC7270627.
8. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in
patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4):844–7. Epub 2020/02/20.
https://doi.org/10.1111/jth.14768 PMID: 32073213; PubMed Central PMCID: PMC7166509.
9. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a
functional receptor for the SARS coronavirus. Nature. 2003; 426(6965):450–4. Epub 2003/12/04.
https://doi.org/10.1038/nature02145 PMID: 14647384; PubMed Central PMCID: PMC7095016.
10. Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic. Stroke. 2020;
51(6):1910–12. Epub 2020/04/03. https://doi.org/10.1161/STROKEAHA.120.030023 PMID: 32233972.
11. Kelly PJ, Murphy S, Coveney S, Purroy F, Lemmens R, Tsivgoulis G, et al. Anti-inflammatory
approaches to ischaemic stroke prevention. Journal of neurology, neurosurgery, and psychiatry. 2017.
https://doi.org/10.1136/jnnp-2016-314817 PMID: 28935831.
12. Purroy F, Montaner J, Molina CA, Delgado P, Arenillas JF, Chacon P, et al. C-reactive protein predicts
further ischemic events in transient ischemic attack patients. Acta neurologica Scandinavica. 2007; 115
(1):60–6. https://doi.org/10.1111/j.1600-0404.2006.00715.x PMID: 17156267.
PLOS ONE Thromboembolic events and prognosis in COVID-19 patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0252351 June 9, 2021 9 / 11
13. Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xiong J, et al. Characteristics and Outcomes in
Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry. Stroke.
2020; 51(9):e254–8. Epub 2020/08/14. https://doi.org/10.1161/STROKEAHA.120.031208 PMID:
32787707; PubMed Central PMCID: PMC7359900.
14. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Present-
ing Feature of Covid-19 in the Young. N Engl J Med. 2020; 382(20):e60. Epub 2020/04/29. https://doi.
org/10.1056/NEJMc2009787 PMID: 32343504; PubMed Central PMCID: PMC7207073.
15. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and Cardiovascular
Disease. Circulation. 2020; 141:1648–55. https://doi.org/10.1161/CIRCULATIONAHA.120.046941
PMID: 32200663
16. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular Consid-
erations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019
(COVID-19) Pandemic. J Am Coll Cardiol. 2020; 75(18). Epub 2020/03/24. https://doi.org/10.1016/j.
jacc.2020.03.031 PMID: 32201335; PubMed Central PMCID: PMC7198856.
17. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardio-
vascular System: A Review. JAMA Cardiol. 2020. Epub 2020/03/29. https://doi.org/10.1001/
jamacardio.2020.1286 PMID: 32219363.
18. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic dis-
eases on COVID-19 in China. Clin Res Cardiol. 2020; 109(5):531–8. Epub 2020/03/13. https://doi.org/
10.1007/s00392-020-01626-9 PMID: 32161990; PubMed Central PMCID: PMC7087935.
19. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients
with coronavirus disease 2019: retrospective study. BMJ. 2020; 368:m1091. Epub 2020/03/29. https://
doi.org/10.1136/bmj.m1091 PMID: 32217556; PubMed Central PMCID: PMC7190011 at www.icmje.
org/coi_disclosure.pdf and declare: support from the Tongji Hospital for Pilot Scheme Project and the
Chinese National Thirteenth Five Years Project in Science and Technology, National Commission of
Health, People’s Republic of China, for the submitted work; no financial relationships with any organisa-
tion that might have an interest in the submitted work in the previous three years; no other relationships
or activities that could appear to have influenced the submitted work.
20. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthen-
ing the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for report-
ing observational studies. J Clin Epidemiol. 2008; 61(4):344–9. Epub 2008/03/04. https://doi.org/10.
1016/j.jclinepi.2007.11.008 PMID: 18313558.
21. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high
cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated
analysis. Thromb Res. 2020; 191:148–50. Epub 2020/05/10. https://doi.org/10.1016/j.thromres.2020.
04.041 PMID: 32381264; PubMed Central PMCID: PMC7192101.
22. Al-Ani F, Chehade S, Lazo-Langner A. Thrombosis risk associated with COVID-19 infection. A scoping
review. Thromb Res. 2020; 192:152–60. Epub 2020/06/03. https://doi.org/10.1016/j.thromres.2020.05.
039 PMID: 32485418; PubMed Central PMCID: PMC7255332.
23. Hippensteel JA, Burnham EL, Jolley SE. Prevalence of Venous Thromboembolism in Critically Ill
Patients with COVID-19. Br J Haematol. 2020. Epub 2020/06/03. https://doi.org/10.1111/bjh.16908
PMID: 32484907.
24. Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in Hospital-
ized Patients With COVID-19 in a New York City Health System. JAMA. 2020. Epub 2020/07/24.
https://doi.org/10.1001/jama.2020.13372 PMID: 32702090; PubMed Central PMCID: PMC7372509.
25. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac
pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet
Respir Med. 2020. Epub 2020/05/31. https://doi.org/10.1016/S2213-2600(20)30243-5 PMID:
32473124; PubMed Central PMCID: PMC7255143.
26. Deshpande C. Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embo-
lism? Ann Intern Med. 2020; 173(5):394–5. Epub 2020/05/19. https://doi.org/10.7326/M20-3255 PMID:
32422061; PubMed Central PMCID: PMC7249508.
27. Schaller T, Hirschbuhl K, Burkhardt K, Braun G, Trepel M, Markl B, et al. Postmortem Examination of
Patients With COVID-19. JAMA. 2020; 323(24):2518–20. Epub 2020/05/22. https://doi.org/10.1001/
jama.2020.8907 PMID: 32437497; PubMed Central PMCID: PMC7243161.
28. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JC, Fogerty AE, Waheed A, et al. COVID and Coagula-
tion: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection. Blood. 2020; 136(4):489–500.
Epub 2020/06/04. https://doi.org/10.1182/blood.2020006520 PMID: 32492712.
29. Maier CL, Truong AD, Auld SC, Polly DM, Tanksley CL, Duncan A. COVID-19-associated hyperviscos-
ity: a link between inflammation and thrombophilia? Lancet. 2020; 395(10239):1758–9. Epub 2020/05/
PLOS ONE Thromboembolic events and prognosis in COVID-19 patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0252351 June 9, 2021 10 / 11
29. https://doi.org/10.1016/S0140-6736(20)31209-5 PMID: 32464112; PubMed Central PMCID:
PMC7247793.
30. COVID-19 coagulopathy: an evolving story. Lancet Haematol. 2020; 7(6):e425. Epub 2020/05/30.
https://doi.org/10.1016/S2352-3026(20)30151-4 PMID: 32470428; PubMed Central PMCID:
PMC7250563.
31. Nguyen JL, Yang W, Ito K, Matte TD, Shaman J, Kinney PL. Seasonal Influenza Infections and Cardio-
vascular Disease Mortality. JAMA Cardiol. 2016; 1(3):274–81. Epub 2016/07/22. https://doi.org/10.
1001/jamacardio.2016.0433 PMID: 27438105; PubMed Central PMCID: PMC5158013.
32. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, et al. Influenza epidemics and
acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart dis-
ease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007; 28(10):1205–10.
Epub 2007/04/19. https://doi.org/10.1093/eurheartj/ehm035 PMID: 17440221; PubMed Central
PMCID: PMC7108465.
33. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocar-
dial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018; 378(4):345–53.
Epub 2018/01/25. https://doi.org/10.1056/NEJMoa1702090 PMID: 29365305.
34. Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-
19) With Myocardial Injury and Mortality. JAMA Cardiol. 2020; 5(7):751–3. Epub 2020/03/29. https://
doi.org/10.1001/jamacardio.2020.1105 PMID: 32219362.
35. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospital-
ized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020; 5(7):802–10. Epub 2020/03/27.
https://doi.org/10.1001/jamacardio.2020.0950 PMID: 32211816; PubMed Central PMCID:
PMC7097841.
36. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of
Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7):811–8. Epub 2020/03/
29. https://doi.org/10.1001/jamacardio.2020.1017 PMID: 32219356; PubMed Central PMCID:
PMC7101506.
37. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;
17(5):259–60. Epub 2020/03/07. https://doi.org/10.1038/s41569-020-0360-5 PMID: 32139904;
PubMed Central PMCID: PMC7095524.
38. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac Involvement in a Patient
With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020. Epub 2020/03/29. https://doi.org/10.
1001/jamacardio.2020.1096 PMID: 32219357.
39. Trimaille A, Curtiaud A, Marchandot B, Matsushita K, Sato C, Leonard-Lorant I, et al. Venous thrombo-
embolism in non-critically ill patients with COVID-19 infection. Thromb Res. 2020; 193:166–9. Epub
2020/07/25. https://doi.org/10.1016/j.thromres.2020.07.033 PMID: 32707275; PubMed Central
PMCID: PMC7367026.
40. Frickmann H, Jungblut S, Hirche TO, Gross U, Kuhns M, Zautner AE. The influence of virus infections
on the course of COPD. Eur J Microbiol Immunol (Bp). 2012; 2(3):176–85. Epub 2012/09/01. https://
doi.org/10.1556/EuJMI.2.2012.3.2 PMID: 24688763; PubMed Central PMCID: PMC3962752.
41. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on
an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46(5):846–8. Epub
2020/03/04. https://doi.org/10.1007/s00134-020-05991-x PMID: 32125452; PubMed Central PMCID:
PMC7080116.
42. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with
SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lan-
cet Respir Med. 2020; 8(5):475–81. Epub 2020/02/28. https://doi.org/10.1016/S2213-2600(20)30079-5
PMID: 32105632; PubMed Central PMCID: PMC7102538.
43. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in
patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;
94:91–5. Epub 2020/03/17. https://doi.org/10.1016/j.ijid.2020.03.017 PMID: 32173574; PubMed Cen-
tral PMCID: PMC7194638.
44. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and
prognosis of COVID-19. Diabetes Metab Res Rev. 2020:e3319. Epub 2020/04/02. https://doi.org/10.
1002/dmrr.3319 PMID: 32233013; PubMed Central PMCID: PMC7228407.
45. Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al. New-Onset Diabetes in Covid-
19. N Engl J Med. 2020. Epub 2020/06/13. https://doi.org/10.1056/NEJMc2018688 PMID: 32530585.
46. Flumignan RL, Tinoco JDS, Pascoal PI, Areias LL, Cossi MS, Fernandes MI, et al. Prophylactic antico-
agulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2020; 10:CD013739.
Epub 2021/01/28. https://doi.org/10.1002/14651858.CD013739 PMID: 33502773.
PLOS ONE Thromboembolic events and prognosis in COVID-19 patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0252351 June 9, 2021 11 / 11
